{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T12:51:13Z","timestamp":1787403073649,"version":"build-2736575974"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,28]]},"DOI":"10.7759\/cureus.86905","type":"journal-article","created":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T11:22:01Z","timestamp":1751109721000},"source":"Crossref","is-referenced-by-count":2,"title":["Pseudoprogression in Hepatocellular Carcinoma During Atezolizumab Plus Bevacizumab Therapy: A Case Report and a Review of Literature"],"prefix":"10.7759","author":[{"given":"Mikee Elaine U","family":"Wee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Hung","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Chao","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Hung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Hung","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour L","year":"2017","unstructured":"Seymour L, Bogaerts J, Perrone A, et al.. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017, 18:e143-52. 10.1016\/S1470-2045(17)30074-8","journal-title":"Lancet Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.0137","article-title":"JAMA Oncology patient page. Immune checkpoint inhibitors","volume":"1","author":"West HJ","year":"2015","unstructured":"West HJ. JAMA Oncology patient page. Immune checkpoint inhibitors. JAMA Oncol. 2015, 1:115. 10.1001\/jamaoncol.2015.0137","journal-title":"JAMA Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.4710-24","article-title":"Hepatocellular carcinoma presenting with pseudoprogression in a patient receiving atezolizumab plus bevacizumab combination therapy","author":"Osuga T","year":"2025","unstructured":"Osuga T, Kubo T, Miyanishi K, et al.. Hepatocellular carcinoma presenting with pseudoprogression in a patient receiving atezolizumab plus bevacizumab combination therapy. Intern Med. 2025, 10.2169\/internalmedicine.4710-24","journal-title":"Intern Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.771887","article-title":"Outcome of initial progression during nivolumab treatment for hepatocellular carcinoma: should we use iRECIST?","volume":"8","author":"Lee DH","year":"2021","unstructured":"Lee DH, Hwang S, Koh YH, et al.. Outcome of initial progression during nivolumab treatment for hepatocellular carcinoma: should we use iRECIST?. Front Med (Lausanne). 2021, 8:771887. 10.3389\/fmed.2021.771887","journal-title":"Front Med (Lausanne)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng AL","year":"2022","unstructured":"Cheng AL, Qin S, Ikeda M, et al.. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022, 76:862-73. 10.1016\/j.jhep.2021.11.030","journal-title":"J Hepatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2020200443","article-title":"Incidence of pseudoprogression during immune checkpoint inhibitor therapy for solid tumors: a systematic review and meta-analysis","volume":"297","author":"Park HJ","year":"2020","unstructured":"Park HJ, Kim KW, Pyo J, Suh CH, Yoon S, Hatabu H, Nishino M. Incidence of pseudoprogression during immune checkpoint inhibitor therapy for solid tumors: a systematic review and meta-analysis. Radiology. 2020, 297:87-96. 10.1148\/radiol.2020200443","journal-title":"Radiology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1177\/23247096211058489","article-title":"A case of pseudoprogression in hepatocellular carcinoma treated with atezolizumab plus bevacizumab","volume":"9","author":"Watanabe Y","year":"2021","unstructured":"Watanabe Y, Ogawa M, Tamura Y, et al.. A case of pseudoprogression in hepatocellular carcinoma treated with atezolizumab plus bevacizumab. J Investig Med High Impact Case Rep. 2021, 9:23247096211058489. 10.1177\/23247096211058489","journal-title":"J Investig Med High Impact Case Rep"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1159\/000527250","article-title":"Atezolizumab and bevacizumab combination therapy and sequential conversion hepatectomy for advanced fibrolamellar hepatocellular carcinoma presenting pseudoprogression","volume":"12","author":"Matsuki R","year":"2023","unstructured":"Matsuki R, Okano N, Hasui N, et al.. Atezolizumab and bevacizumab combination therapy and sequential conversion hepatectomy for advanced fibrolamellar hepatocellular carcinoma presenting pseudoprogression. Liver Cancer. 2023, 12:180-3. 10.1159\/000527250","journal-title":"Liver Cancer"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s12328-023-01761-6","article-title":"A case of hepatocellular carcinoma with \"pseudoprogression\" followed by complete response to atezolizumab plus bevacizumab","volume":"16","author":"Odagiri N","year":"2023","unstructured":"Odagiri N, Tamori A, Kotani K, et al.. A case of hepatocellular carcinoma with \"pseudoprogression\" followed by complete response to atezolizumab plus bevacizumab. Clin J Gastroenterol. 2023, 16:392-6. 10.1007\/s12328-023-01761-6","journal-title":"Clin J Gastroenterol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.9701-22","article-title":"Hepatocellular carcinoma pseudoprogression involving the main portal vein, right ventricular invasion, and exacerbation of lung metastases in a patient on atezolizumab plus bevacizumab","volume":"62","author":"Shigefuku R","year":"2023","unstructured":"Shigefuku R, Yoshikawa K, Tsukimoto M, et al.. Hepatocellular carcinoma pseudoprogression involving the main portal vein, right ventricular invasion, and exacerbation of lung metastases in a patient on atezolizumab plus bevacizumab. Intern Med. 2023, 62:539-43. 10.2169\/internalmedicine.9701-22","journal-title":"Intern Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.2349-23","article-title":"Contrast-enhanced ultrasonography features for diagnosing pseudoprogression of hepatocellular carcinoma with immunotherapy: a case report of the response after pseudoprogression","volume":"63","author":"Otake S","year":"2024","unstructured":"Otake S, Ota Y, Aso K, et al.. Contrast-enhanced ultrasonography features for diagnosing pseudoprogression of hepatocellular carcinoma with immunotherapy: a case report of the response after pseudoprogression. Intern Med. 2024, 63:1093-7. 10.2169\/internalmedicine.2349-23","journal-title":"Intern Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.17235\/reed.2024.10942\/2024","article-title":"Pseudoprogression in a patient with hepatocellular carcinoma treated with immunotherapy plus bevacizumab","author":"D\u00edaz L\u00f3pez S","year":"2024","unstructured":"D\u00edaz L\u00f3pez S, Jimeno Mat\u00e9 C, Fern\u00e1ndez Parra EM, S\u00e1nchez Vegas A. Pseudoprogression in a patient with hepatocellular carcinoma treated with immunotherapy plus bevacizumab. Rev Esp Enferm Dig. 2024, 10.17235\/reed.2024.10942\/2024","journal-title":"Rev Esp Enferm Dig"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2023.08.062","article-title":"Efficacy of immunotherapy in hepatocellular carcinoma: does liver disease etiology have a role?","volume":"56","author":"Pinto E","year":"2024","unstructured":"Pinto E, Meneghel P, Farinati F, Russo FP, Pelizzaro F, Gambato M. Efficacy of immunotherapy in hepatocellular carcinoma: does liver disease etiology have a role?. Dig Liver Dis. 2024, 56:579-88. 10.1016\/j.dld.2023.08.062","journal-title":"Dig Liver Dis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-025-13978-4","article-title":"Predicting treatment response and prognosis of immune checkpoint inhibitors-based combination therapy in advanced hepatocellular carcinoma using a longitudinal CT-based radiomics model: a multicenter study","volume":"25","author":"Xu J","year":"2025","unstructured":"Xu J, Li J, Wang T, et al.. Predicting treatment response and prognosis of immune checkpoint inhibitors-based combination therapy in advanced hepatocellular carcinoma using a longitudinal CT-based radiomics model: a multicenter study. BMC Cancer. 2025, 25:602. 10.1186\/s12885-025-13978-4","journal-title":"BMC Cancer"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-70208-w","article-title":"CT radiomics-based biomarkers can predict response to immunotherapy in hepatocellular carcinoma","volume":"14","author":"Qi L","year":"2024","unstructured":"Qi L, Zhu Y, Li J, Zhou M, Liu B, Chen J, Shen J. CT radiomics-based biomarkers can predict response to immunotherapy in hepatocellular carcinoma. Sci Rep. 2024, 14:20027. 10.1038\/s41598-024-70208-w","journal-title":"Sci Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/379731-pseudoprogression-in-hepatocellular-carcinoma-during-atezolizumab-plus-bevacizumab-therapy-a-case-report-and-a-review-of-literature","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T11:22:02Z","timestamp":1751109722000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/379731-pseudoprogression-in-hepatocellular-carcinoma-during-atezolizumab-plus-bevacizumab-therapy-a-case-report-and-a-review-of-literature"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,28]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.86905","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,28]]}}}